Physician-perceived frailty and low life expectancy are the main reasons for warfarin discontinuation in elderly patients
Machaon Diagnostics has launched a same-day genetic testing service for patients that have been prescribed warfarin (Coumadin, from Bristol-Myers Squibb).
Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
After transcatheter aortic valve implantation (TAVI) there is no increased risk of bleeding or other adverse outcomes for those patients who have an indication for anticoagulant therapy.
Drugs in the Pipeline
Johnson & Johnson Pharmaceutical Research & Development announced results from its Phase 3 study of rivaroxaban in non-valvular atrial fibrillation (AF) patients to reduce the risk of stroke and non-CNS systemic embolism.
Most people with nonvalvular atrial fibrillation (NVAF) should be taking oral anticoagulants to prevent stroke.
For patients on warfarin with minor head trauma who have an initial negative computed tomography (CT) scan, 24-hour observation followed by an additional CT scan identifies the majority of cases of delayed bleeding.
Patients with heart valve replacements have greater rates of thromboembolic and bleeding complications after treatment with dabigatran vs. warfarin.
Despite trend toward lower stroke risk with high dose
A prospective phase 2 study of the low-molecular-weight heparin (LMWH) tinzaparin for initial treatment and secondary prophylaxis of venous thromboembolism (VTE) associated with cancer treatment found the agent to be safe and efficacious, with the recurrent VTE event rate comparing favorably with that reported for another LMWH, dalteparin according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.